Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 55, Issue 4, Pages 1751-1757Publisher
AMER CHEMICAL SOC
DOI: 10.1021/jm201524g
Keywords
-
Categories
Ask authors/readers for more resources
A high-throughput screen against human DGAT-1 led to the identification of a core structure that was subsequently optimized to afford the potent, selective, and orally bioavailable compound 14. Oral administration at doses >= 0.03 mg/kg significantly reduced postprandial triglycerides in mice following an oral lipid challenge. Further assessment in both acute and chronic safety pharmacology and toxicology studies demonstrated a clean profile up to high plasma levels, thus culminating in the nomination of 14 as clinical candidate ABT-046.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available